A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM)
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs AG 10 (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Registrational; Therapeutic Use
- Acronyms ATTRibute-CM
- Sponsors Eidos Therapeutics
- 19 Nov 2019 Planned End Date changed from 1 Nov 2022 to 1 May 2023.
- 19 Nov 2019 Planned primary completion date changed from 1 Oct 2022 to 1 Apr 2023.
- 16 Nov 2019 According to an BridgeBio Pharma media release, the enrollment for Part A of this study is projected to complete in the second half of 2020, with top-line data expected in 2021.